相关实验视频
Updated: May 23, 2025

05:07
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
6.6K
和酸衍生物的合成:抗癌和分子对接研究
Prabhakar Shetti1, Vitthalrao Kashid1, Nilesh Wankhede1
1Technical & Applied Chemistry Department, Veermata Jijabai Technological Institute, H.R. Mahajani Marg, Matunga, Mumbai, 400019, India.
ChemPlusChem
|March 7, 2025
概括
新的化和化衍生物显示出显著的抗癌潜力. 化合物3e和4c有效向乳腺癌细胞,而3d和4b抑制肺癌细胞,诱导细胞亡和细胞循环停止.
科学领域:
- 药用化学 医学化学
- 有机合成 有机合成
- 癌症生物学 癌症生物学
背景情况:
- 皮拉衍生物因其多样化的生物活性而得到认可.
- 开发新的抗癌药物仍然是研究的关键领域.
- 针对乳腺癌和肺癌等特定癌症细胞系需要创新的化学支架.
研究的目的:
- 为了合成和表征新的和酸衍生物.
- 为了评估这些化合物的体外细胞毒性对人类乳腺癌 (MCF-7) 和肺癌 (A549) 细胞系.
- 研究作用机制,包括细胞循环停止,细胞亡诱导和PARP抑制.
主要方法:
- 通过使用PEG-400作为绿色溶剂,通过克莱森 - 施密特凝结合成石墨烯中间体.
- 用替代的基酸盐和替代的基酸盐循环制造,以产生pyrazoline衍生物.
- 在体外细胞毒性评估使用MTT试验,流细胞计用于细胞周期分析,细胞亡试验,PARP抑制试验和分子对接研究.
主要成果:
- 成功合成和表征化和酸酸衍生物.
- 化合物3e和4c对MCF-7细胞表现出显著的细胞毒性;化合物3d和4b对A549细胞表现出显著的抑制.
- 流细胞计显示了G1/S阶段细胞周期停止和亡诱导. 化合物4c表现出相当大的PARP抑制,得到分子对接的支持.
结论:
- 合成的pyrazoline衍生物具有有前途的抗癌性质.
- 化合物3e,4c,3d和4b通过诱导细胞循环停止和细胞亡,对特定的癌症细胞系有效.
- 化合物4c显示出作为PARP抑制剂的潜力,这表明癌症治疗的可行治疗策略.
相关概念视频
Basicity of Heterocyclic Aromatic Amines
5.5K
Heterocyclic amines, where the N atom is a part of an alicyclic system, are similar in basicity to alkylamines. Interestingly, the heterocyclic amine having a nitrogen atom as part of an aromatic ring has much less basicity than its corresponding alicyclic counterpart. For this reason, as presented in Figure 1, piperidine (pKb = 2.8) is significantly more basic than pyridine (pKb = 8.8).
5.5K
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
2.9K
The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the...
2.9K

